Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Assets (QoQ)Assets Growth (1y)Capital Expenditures (QoQ)Capital Expenditures Growth (1y)Cash & Equivalents (QoQ)Cash & Equivalents Growth (1y)Cash from Investing Activities (QoQ)Cash from Investing Activities Growth (1y)Cash from Operations (QoQ)Cash from Operations Growth (1y)EBIT (QoQ)EBIT Growth (1y)EBIT Margin (QoQ)EBIT Margin Growth (1y)EBITDA Margin (QoQ)EBITDA Margin Growth (1y)EBT (QoQ)EBT Growth (1y)EBT Margin (QoQ)EBT Margin Growth (1y)EPS (Basic) (QoQ)EPS (Basic) Growth (1y)EPS (Weighted Average and Diluted) (QoQ)EPS (Weighted Average and Diluted) Growth (1y)Enterprise Value (QoQ)Enterprise Value Growth (1y)FCF Margin (QoQ)FCF Margin Growth (1y)Free Cash Flow (QoQ)Free Cash Flow Growth (1y)Gross Margin (QoQ)Gross Margin Growth (1y)Gross Profit (QoQ)Gross Profit Growth (1y)Interest Coverage Ratio (QoQ)Interest Coverage Ratio Growth (1y)Net Cash Flow (QoQ)Net Cash Flow Growth (1y)Net Income (QoQ)Net Income Growth (1y)Net Income towards Common Stockholders (QoQ)Net Income towards Common Stockholders Growth (1y)Net Margin (QoQ)Net Margin Growth (1y)Operating Income (QoQ)Operating Income Growth (1y)Operating Margin (QoQ)Operating Margin Growth (1y)Profit After Tax (QoQ)Profit After Tax Growth (1y)Property, Plant & Equipment (Net) (QoQ)Property, Plant & Equipment (Net) Growth (1y)Return on Assets (QoQ)Return on Assets Growth (1y)Return on Capital Employed (QoQ)Return on Capital Employed Growth (1y)Return on Equity (QoQ)Return on Equity Growth (1y)Return on Sales (QoQ)Return on Sales Growth (1y)Revenue (QoQ)Revenue Growth (1y)Share-based Compensation (QoQ)Share-based Compensation Growth (1y)Shareholder's Equity (QoQ)Shareholder's Equity Growth (1y)Total Debt (QoQ)Total Debt Growth (1y)
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned
Lexicon Pharmaceuticals (LXRX) Finished Goods (2023)
Generated on {Timestamp}
© BusinessQuant.com
Generated on {Timestamp}
Powered by 
Lexicon Pharmaceuticals (LXRX) has disclosed Finished Goods for 1 consecutive years, with $172000.0 as the latest value for Q2 2023.
Peer Comparison
Historic Data
Download Data 🔒| Date | Value |
|---|---|